Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
23 ESR1 and 11 ESR2 tag-SNPs, covering most of the common haplotype variation in each gene according to HAPMAP data, were analysed by Chi2 for association with obesity in a cohort comprising 705 adults with severe obesity and 402 lean individuals.
|
18053221 |
2007 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Obesity increases the risk of cancer death among postmenopausal women with estrogen receptor-positive (ER+) breast cancer, but the direct evidence for the mechanisms is lacking.
|
24957076 |
2014 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Obesity is associated with a worse breast cancer prognosis, particularly in estrogen receptor alpha (ERα) positive, postmenopausal patients.
|
25476497 |
2015 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Obesity was significantly associated with differential methylation (FDR q < 0.05) in just two gene loci in breast tumor tissue overall and in 21 loci among ER-positive tumors.
|
25583948 |
2015 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Obesity is an established risk factor for postmenopausal breast cancer (BCa), insulin resistance, and vitamin D deficiency, and all contribute to increased synthesis of mammary estrogens, the drivers of estrogen receptor-positive (ER+) BCa growth.
|
26817629 |
2016 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Obesity is a consideration in the pharmacologic intervention for estrogen receptor (ER) positive (ER+) breast cancer risk.
|
28912152 |
2017 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Obesity reversibly depletes the basal cell population and enhances mammary epithelial cell estrogen receptor alpha expression and progenitor activity.
|
29187227 |
2017 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Obesity is associated with an increased risk of breast cancer, including the estrogen receptor (ER)-positive subtype in postmenopausal women.
|
30520976 |
2019 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Obesity is a risk factor for estrogen receptor-positive (ER+) breast cancer after menopause.
|
30851382 |
2019 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Obesity had a negative impact on improvement in the DAS with 28 joints using ESR as an inflammation marker of -0.15 (95% CI: -0.26; -0.04) units for women receiving conventional synthetic DMARDs, -0.22 (95% CI: -0.31; -0.12) units for women receiving TNF inhibitors, -0.22 (95% CI: -0.42; -0.03) units for women receiving tocilizumab and -0.41 (95% CI: -0.74; -0.07) units for men receiving tocilizumab.
|
31745566 |
2019 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Adding dichotomous tumor ER or PR status to the panel of standard predictors did not improve both model discrimination and calibration.<b>Conclusions:</b> Obesity may be associated with greater endometrial tumor expression of ER and PR.
|
28052940 |
2017 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although it has been well-documented that obesity is associated with decreased risk of premenopausal breast cancer and increased risk of postmenopausal breast cancer, it is unclear whether these associations differ among breast cancer subtypes defined by the tumor protein expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
|
29357906 |
2018 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Aromatase inhibitors are the preferred treatment for certain women with estrogen receptor (ER)-positive breast cancer, but evidence suggests that women with obesity experience aromatase inhibitor resistance at higher rates.
|
31002529 |
2019 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between VDR and ESR1 gene polymorphisms with bone and obesity phenotypes in Chinese male nuclear families.
|
19960008 |
2009 |
Obesity
|
0.600 |
Biomarker
|
disease |
CTD_human |
Biological and biochemical consequences of global deletion of exon 3 from the ER alpha gene.
|
20667977 |
2010 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
BMI was positively associated with all-cause mortality for women diagnosed at age > or =50 years with ER-positive tumors (compared with normal-weight women, HR for overweight = 1.39, 95% CI: 0.90-2.15; HR for obese = 1.77, 95% CI: 1.11-2.82).
|
20140702 |
2010 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CNM (1) normalized serum estradiol-17β levels, (2) induced gastric Nrf2 and phase II antioxidant enzymes through extracellular signal-regulated kinase, (ERK)/c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinase (MAPK), (3) reduced glucose synthase kinase 3 beta (GSK3β) and aryl hydrocarbon receptor (AhR) and this was associated with (4) increased estrogen receptor expression, BH<sub>4</sub> (Cofactor of nNOS) biosynthesis enzyme GCH-1 and nNOSα dimerization in WT Obese/T2 diabetic female mice.
|
30831189 |
2019 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Considering that inactivation of estrogen receptor (ER)α promotes obesity and metabolic dysfunction in women and female mice, understanding the mechanisms and tissue-specific sites of ERα action to combat metabolic-related disease, including BrCA, is of clinical importance.
|
25468909 |
2015 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Disease activity was assessed by DAS28-ESR, and obesity was determined by waist circumference (WC), BMI and dual-energy X-ray absorptiometry (DXA).
|
29947997 |
2018 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling.
|
30862719 |
2019 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genotypes for ACE, GCK, and ESR1 may prove reliable for the assessment of genetic factors for obesity.
|
17016614 |
2006 |
Obesity
|
0.600 |
Biomarker
|
disease |
RGD |
Here we investigated the role of ER alpha and ER beta in a model of nutrition induced obesity.
|
22230815 |
2012 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we identified regulatory pathways in estrogen receptor-positive (ER-positive) tumors that were shared between patients with obesity and those with resistance to neoadjuvant aromatase inhibition.
|
30046001 |
2018 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Herein, we found that BMP4 deficiency in white adipose tissue (WAT) increased the estrogen receptor α (ERα) level and its signaling, which prevented adult female mice from developing high fat diet (HFD)-induced obesity and insulin resistance; estrogens depletion up regulated BMP4 expression to overcome overt adiposity and impaired insulin sensitivity with aging, and failure of BMP4 regulation due to genetic knockout led to more fat gain in aged female mice.
|
27522322 |
2016 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In multiple public expression data sets of breast cancers (representing > 1,500 patients), manifestation of the obesity signature patterns correlated with manifestation of a gene signature for IGF signaling and (to a lesser extent) with lower levels of estrogen receptor.
|
21750966 |
2012 |